832-79-1

Basic information

• Product Name: 1,3,4-Thiadiazol-2-amine, 5-(2-nitrophenyl)-
• CAS NO: 832-79-1
• Molecular Formula: C8H6N4O2S
• Molecular Weight: 222.227
• Mol File: 832-79-1.mol
• Article Data: 22

Chemical Properties

• CAS DataBase Reference: 1,3,4-Thiadiazol-2-amine, 5-(2-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,4-Thiadiazol-2-amine, 5-(2-nitrophenyl)-(832-79-1)
• EPA Substance Registry System: 1,3,4-Thiadiazol-2-amine, 5-(2-nitrophenyl)-(832-79-1)

Safety Data

• Hazardous Substances Data: 832-79-1(Hazardous Substances Data)

Usage

Classification

Heterocyclic organic compound

Structure

Nitro-substituted derivative of 1,3,4-thiadiazol-2-amine

Potential applications

Medicinal chemistry and pharmaceuticals

Use

Synthesis of novel drugs and biologically active molecules

Therapeutic effects

Potential therapeutic effects

Additional applications

Material science and industrial processes

Versatility

Valuable compound in various fields of science and technology

Upstream product

• 1489265-34-0 (2E)-2-[(2-nitrophenyl)methylidene]hydrazine-1-carbothioamide 
• 79-19-6 thiosemicarbazide 
• 552-89-6 2-nitro-benzaldehyde 
• 606-26-8 o-nitrobenzohydrazide 
• 552-16-9 ortho-nitrobenzoic acid 
• 6072-63-5 2-(2-nitrobenzylidene)hydrazinecarbothioamide 
• 835-14-3 N₂-(2-nitrobenzoyl)thiosemicarbazide 
• 2290-65-5 trimethylsilyl isothiocyanate 

Downstream Products

• 1148122-52-4 N-(5-(2-nitrophenyl)-1,3,4-thiadiazol-2-yl)morpholine-4-carboxamide 
• 1148122-49-9 N-(5-(2-nitrophenyl)-1,3,4-thiadiazol-2-yl)methanesulfonamide 
• 1148122-35-3 2-bromo-5-(2-nitrophenyl)-1,3,4-thiadiazole 
• 1293365-99-7 2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-(5-2-nitrophenyl-1,3,4-thiadiazol-2-yl)acetamide 
• 113111-44-7 2-chloro-5-(2-nitrophenyl)-1,3,4-thiadiazole 
• 83543-30-0 α-(5-o-nitrophenyl-1,3,4-thiadiazol-2-yl-amino)-(3,5-dibromo-2-hydroxyphenyl)acetonitrile 
• 83530-81-8 α-(5-o-nitrophenyl-1,3,4-thiadiazol-2-yl-amino)-(3-bromo-2-hydroxyphenyl)acetonitrile 

Relevant articles and documents

Synthesis, in vitro thymidine phosphorylase activity and molecular docking study of thiadiazole bearing isatin analogs

A series of seventeen analogs (1─17) were synthesized and characterized through different spectroscopic techniques such as 1H, 13CNMR, HR-EI-MS and were evaluated for in vitro thymidine phosphorylase inhibition. All compounds showed excellent to good thymidine phosphorylase activity having IC50 value ranging between 4.10 ± 0.20 and 54.60 ± 1.40?μM when compared with standard drug 7-deazaxanthine (IC50 = 38.68 ± 1.12?μM). Among the series, compounds 1 (IC50 = 8.30 ± 0.30?μM), 6 (IC50 = 6.30 ± 0.10?μM), 11 (IC50 = 8.40 ± 0.30?μM) and 16 (IC50 = 4.10 ± 0.20?μM) were found more potent. Potent compounds were further subjected to molecular docking study to identify their interactions with the active site of amino acid. Structure activity relationship was done for all analogs mostly based on substitution pattern on phenyl and isatin rings. Graphic abstract: [Figure not available: see fulltext.]

N-(5-phenyl-1, 3, 4-thiadiazole-2-yl) benzamide compound

The invention belongs to the technical field of medicines, relates to a compound with antitumor activity and a specific chemical structure, and in particular relates to an N-((6, 7-dimethoxyquinoline-4-yl) oxy) methyl)-N-(5-phenyl-1, 3, 4-thiadiazole-2-yl) benzamide compound and a preparation method and an application thereof. The structural general formula of the compound is shown in the specification, wherein an R group is mono-substituted or double-substituted phenyl, fluorophenyl, chlorphenyl, bromophenyl, benzyl, benzyloxy, benzene nitro or trifluoromethyl substituted at 2-position, 3-position or 4-position. Pharmacological studies show that the compound provided by the invention has a relatively remarkable proliferation inhibition effect on HER-2 positive breast cancer cells SK-Br-3, the effect is obviously superior to that of HER-2 negative breast cancer cells MCF-7, the compound can be used for preparing antitumor drugs, and a new way is opened up for deep research and development of tumor drugs in the future. The preparation method provided by the invention is simple and feasible, relatively high in yield and easy for large-scale production.

Synthesis and antiviral activity of novel 1,3,4-thiadiazole inhibitors of DDX3x

The human ATPase/RNA helicase X-linked DEAD-box polypeptide 3 (DDX3X) emerged as a novel therapeutic target in the fight against both infectious diseases and cancer. Herein, a new family of DDX3X inhibitors was designed, synthesized, and tested for its inhibitory action on the ATPase activity of the enzyme. The potential use of the most promising derivatives it has been investigated by evaluating their anti-HIV-1 effects, revealing inhibitory activities in the low micromolar range. A preliminary ADME analysis demonstrated high metabolic stability and good aqueous solubility. The promising biological profile, together with the suitable in vitro pharmacokinetic properties, make these novel compounds a very good starting point for further development.